OncoMatch/Clinical Trials/NCT05621668
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
Is NCT05621668 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Cyclophosphamide and attIL2-T cells for soft tissue sarcoma.
Treatment: Cyclophosphamide · attIL2-T cells — To find a recommended dose of attIL2-T cell therapy that can be given to patients with soft tissue or bone sarcomas and to see if it can help to control the disease.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Sarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Blood counts
ANC ≥ 1 K/uL, Hemoglobin ≥ 9 g/dL, Platelets ≥ 100 K/mm3
Kidney function
Serum creatinine ≤ 2 mg/dL OR creatinine clearance > 50 mL/min
Liver function
AST ≤ 1.5 x ULN, ALT ≤ 1.5 x ULN, Bilirubin ≤ 1.5 x ULN
Cardiac function
LVEF >50%
Absolute neutrophil count (ANC) ≥ 1 K/uL, Hemoglobin ≥ 9 g/dL, Platelets ≥100 K/mm3; Serum creatinine ≤ 2 mg/dL OR creatinine clearance > 50 mL/min; AST ≤ 1.5 x ULN, ALT ≤ 1.5 x ULN, Bilirubin ≤ 1.5 x ULN; Cardiac function: LVEF >50%; Pulmonary function: Oxygen saturation >92% on room air, Total lung capacity >70% of predicted, DLCO >60% of predicted
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05621668 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages